Pay with Crypto and get 10% off your order!
HDL-P, a measurement of total HDL particle number concentration, may be a better marker of residual risk than chemically measured high-density lipoprotein cholesterol (HDL-C, the so-called “good” cholesterol) or apolipoprotein A-1 (apoA-1, the major protein on HDL), ie, there may be a more consistent inverse association between cardiovascular endpoints and HDL-P compared with HDL-C.
Direct quantification of HDL-P concentration by NMR may be useful to refine cardiovascular risk and to evaluate novel HDL-directed therapies. Further studies are needed to clarify the role of HDL-P in clinical practice.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
